Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy
International Journal of Neonatal Screening · 25.12.2023 · 10 (1) · 3
DOI: 10.3390/ijns10010003 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 25.12.2023. Verfasst von Vincenza Gragnaniello und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital of Padua, 35128 Padua, Italy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In the last two decades, the development of high-throughput diagnostic methods and the availability of effective treatments have increased the interest in newborn screening for lysosomal storage disorders. However, long-term follow-up experience is needed to clearly identify risks, benefits and challenges. We report our 8-year experience of screening and follow-up on about 250,000 neonates screened for four lysosomal storage diseases (Pompe disease, mucopolysaccharidosis type I, Fabry disease, Gaucher disease), using the enzyme activity assay by tandem mass spectrometry, and biomarker quantification as a second-tier test. Among the 126 positive newborns (0.051%), 51 infants were confirmed as affected (positive predictive value 40%), with an overall incidence of 1:4874. Of these, three patients with infantile-onset Pompe disease, two with neonatal-onset Gaucher disease and four with mucopolysaccharidosis type I were immediately treated. Furthermore, another four Gaucher disease patients needed treatment in the first years of life. Our study demonstrates the feasibility and effectiveness of newborn screening for lysosomal storage diseases. Early diagnosis and treatment allow the achievement of better patient outcomes. Challenges such as false-positive rates, the diagnosis of variants of uncertain significance or late-onset forms and the lack of treatment for neuronopathic forms, should be addressed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Inherited Metabolic Diseases, Department of Diagnostic Services, University Hospital of Padua, 35128 Padua, Italy.
- Division of Inherited Metabolic Diseases, Department of Women's and Children's Health, University of Padua, 35128 Padua, Italy.
- Clinical Genetics Unit, Department of Women's and Children's Health, University of Padua, 35128 Padua, Italy.
- Neurology Unit, St Bassiano Hospital, 36061 Bassano del Grappa, Italy.
ORCID-Profile: Elena Porcù, Paolo Miglioranza, Alessandro P Burlina, Alberto B Burlina
Zitieren
APA
Gragnaniello, V., Cazzorla, C., Gueraldi, D., Puma, A., Loro, C., Porcù, E., Stornaiuolo, M., Miglioranza, P., Salviati, L., Burlina, A. P., & Burlina, A. B. (2023). Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy. International Journal of Neonatal Screening, 10(1), 3. https://doi.org/10.3390/ijns10010003
Vancouver
Gragnaniello V, Cazzorla C, Gueraldi D, Puma A, Loro C, Porcù E, et al. Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy. International Journal of Neonatal Screening. 2023;10(1):3. doi:10.3390/ijns10010003
BibTeX
@article{Gragnaniello2023,
author = {Gragnaniello, Vincenza and Cazzorla, Chiara and Gueraldi, Daniela and Puma, Andrea and Loro, Christian and Porcù, Elena and Stornaiuolo, Maria and Miglioranza, Paolo and Salviati, Leonardo and Burlina, Alessandro P and Burlina, Alberto B},
title = {Light and Shadows in Newborn Screening for Lysosomal Storage Disorders: Eight Years of Experience in Northeast Italy},
journal = {International Journal of Neonatal Screening},
year = {2023},
volume = {10},
number = {1},
pages = {3},
doi = {10.3390/ijns10010003}
}
EUVIMED